Orphazyme A/S is a renowned biopharmaceutical company committed to developing innovative treatments for rare diseases. With a strong corporate philosophy, Orphazyme focuses on bringing hope and improving the lives of patients worldwide. The company values integrity, collaboration, and a patient-centric approach. Orphazyme is dedicated to conducting thorough research and clinical trials to deliver safe and effective therapies. By leveraging their expertise in protein degradation, Orphazyme seeks to address unmet medical needs and make a meaningful impact in the rare disease community. Through their dedication and passion, Orphazyme A/S aims to provide transformative treatments and improve patient outcomes.

Orphazyme A/S is primarily present in several countries and regions. These include the United States, where the company is headquartered, as well as various European countries such as Denmark, Germany, France, and the United Kingdom. Additionally, Orphazyme A/S has a strong presence in Scandinavia, specifically in Norway and Sweden. The company's global outreach reflects its commitment to expanding its innovative treatments and therapies for rare genetic diseases across multiple markets.

Orphazyme A/S has achieved several significant milestones in its journey. The company successfully completed its IPO in Copenhagen, Denmark, raising funds to support its pipeline development. Orphazyme A/S has also received orphan drug designations from the U.S. FDA for its lead product candidate, arimoclomol, for the treatment of Niemann-Pick disease Type C (NPC) and sporadic Inclusion Body Myositis (sIBM). Furthermore, the company has advanced arimoclomol into late-stage clinical trials for NPC and sIBM. These achievements highlight Orphazyme A/S's commitment to addressing unmet medical needs and advancing innovative therapies for patients with rare diseases.

Orphazyme A/S is a biopharmaceutical company specializing in the development of innovative treatments for rare neurodegenerative diseases. Established in 2009 in Denmark, Orphazyme has focused on developing therapies that target protein misfolding and aggregation, which are underlying causes of many rare diseases. The company's flagship product, arimoclomol, aims to treat diseases such as Niemann-Pick disease type C (NPC) and sporadic Inclusion Body Myositis (sIBM), among others. Orphazyme has conducted extensive research and clinical trials to demonstrate the safety and efficacy of their treatments. With a mission to improve patients' lives, Orphazyme is dedicated to providing hope to individuals battling rare diseases.

The main competitors of Orphazyme A/S in the market are Alexion Pharmaceuticals, Amicus Therapeutics, BioMarin Pharmaceutical, and Sanofi Genzyme.

Orphazyme A/S is primarily active in the pharmaceutical industry.

The business model of Orphazyme A/S is focused on the development of novel therapies for the treatment of rare and devastating diseases. Orphazyme A/S utilizes its proprietary Heat-Shock Protein response platform to identify potential drug candidates that can restore cellular function and alleviate the symptoms of these diseases. The company's lead drug candidate, arimoclomol, is currently being evaluated for the treatment of four rare diseases, including Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. Orphazyme A/S aims to bring innovative treatments to patients suffering from rare diseases and improve their quality of life.

Orphazyme A/S KGV ir 15,68.

Orphazyme A/S KUV ir 0,01.

AlleAktien kvalitātes vērtējums Orphazyme A/S ir 1/10.

gaidāmā Orphazyme A/S apgrozījums ir 4,14 miljardi DKK.

gaidāmā Orphazyme A/S peļņa ir 2,00 milj. DKK.

Orphazyme A/S is a Danish biotechnology company specializing in the development of therapy options for rare diseases. The company's business model is based on identifying and developing innovative therapies for rare genetic diseases that currently have no effective treatment options. The company focuses on protein-folding diseases, where proteins in the body's cells are folded incorrectly, leading to toxic buildup and various symptoms. Orphazyme has developed a unique technology platform to help treat these diseases. The company conducts both research and development of novel therapeutics, utilizing advanced technology such as artificial intelligence to identify promising drug candidates and test them in clinical trials. The company aims to take a leadership role in the field of protein folding therapies and has a pipeline of potential products in development. Their flagship product is Arimoclomol, an oral medication developed for the treatment of Amyotrophic Lateral Sclerosis (ALS). It has already been tested in clinical trials and is currently in the approval process. In addition, the company is working on the development of new drugs for diseases such as Niemann-Pick disease and Frontotemporal Dementia. Orphazyme has a multi-stage strategy to bring its products to market, including identifying potential therapeutics, conducting clinical trials, submitting regulatory applications, and collaborating with partners to ensure global marketing and distribution of products. Their partners include large pharmaceutical companies and clinical research organizations that support the company in conducting studies and marketing their products. The company also forms partnerships with patient and research organizations to gain comprehensive insights into rare diseases and advance the development of therapeutics. In summary, Orphazyme A/S's business model is based on identifying and developing therapies for rare genetic diseases that currently lack effective treatment options. The company utilizes advanced technology and collaborates with partners to market its products globally. With products like Arimoclomol and a pipeline of promising therapeutics, the company strives to improve the lives of people with rare diseases.

Orphazyme A/S izmaksā dividendes 0 DKK, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Orphazyme A/S vai uzņēmums nedod dividendes.

Orphazyme A/S ISIN ir DK0060910917.

Orphazyme A/S WKN ir A2H7EV.

Orphazyme A/S simbols ir ORPHA.CO.

Pēdējo 12 mēnešu laikā Orphazyme A/S maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Orphazyme A/S plāno maksāt dividendes 0 DKK apmērā.

Orphazyme A/S pašreizējā dividendu rentabilitāte ir .

Orphazyme A/S maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Orphazyme A/S pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 DKK. Tas atbilst dividendes ražībai 0 %.

Orphazyme A/S tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Orphazyme A/S apmērā 0 DKK, kas tika izmaksāta 21.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 21.09.2024..

Pēdējās dividendes izmaksa notika 21.09.2024..

Gadā 2023, Orphazyme A/S izmaksāja 0 DKK dividendes.

Orphazyme A/S dividendes tiek izmaksātas DKK.